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 Do endovascular fi lters 
prevent PE as eff ectively as anti-
coagulants in patients with DVT?
EVIDENCE-BASED ANSWER
A it’s unclear, given that no studies directly compare the effi  cacy of en-
dovascular fi lters with other types of prophy-
laxis to prevent pulmonary embolism (PE) in 
adults with deep venous thrombosis (DVT). 
Although inferior vena cava fi lters 
(IVCFs) reduced the incidence of PE in a 
randomized controlled trial (RCT), patients 
treated with IVCFs and anticoagulation 
with unfractionated heparin or low-
molecular-weight heparin had a greater 
risk of developing recurrent DVT than pa-
tients treated with anticoagulation alone 
(SOR: B, 1 RCT). 
Patients should be considered for IVCF 
placement in the following circumstances 
(SOR: C, consensus guideline):
 • anticoagulation is contraindicated
 •  a serious complication has resulted 
from anticoagulation treatment
 •  thromboembolism recurs despite ad-
equate anticoagulation. 
Evidence summary
One RCT examined PE rates in 400 patients 
with acute proximal DVT who were random-
ized to receive or not receive a permanent 
IVCF and also randomized to receive either 
unfractionated heparin or low-molecular-
weight heparin for at least the fi rst 3 months.1,2 
Patients with a contraindication to antico-
agulation or history of anticoagulation failure 
were excluded. 
After 8 years of follow-up, symptomatic 
PE occurred less often in the fi lter group than 
the nonfi lter group (6.2% vs 15.1%; P=.008; 
hazard ratio [HR]=0.36, 95% confi dence in-
terval [CI], 0.17-0.77; number needed to treat 
[NNT]=11.2). Th e fi lter group had a higher in-
cidence of recurrent DVT than the nonfi lter 
group (35.7% vs 27.5%; HR=1.52, 95% CI, 1.02-
2.27; number needed to harm=12.2).1,2 
Th e study lacked statistical power to draw 
any conclusion about the effi  cacy of IVCFs in 
preventing PE over shorter time periods or 
in reducing PE-related or overall mortality.3 
Further research, including RCTs, needs to 
be done to determine how the effi  cacy of en-
dovascular fi lters compares with standard PE 
prophylaxis.
How often does PE occur 
in patients with ﬁ lters?
Patients with DVT generally have associated PE 
10% of the time.4 Several cohort studies have 
examined the prevalence of recurrent PE in pa-
tients with IVCFs, but none compared preva-
lence in patients with and without fi lters. 
A prospective cohort study followed 481 
patients who received an IVCF because of ei-
ther a contraindication to anticoagulation or 
sustained recurrent embolization despite ad-
equate anticoagulation. Of the patients who 
had a fi lter for 6 months or longer, 2% had 
clinically suspected PE, but PE was confi rmed 
in only 0.5%.5 
Another multicenter, prospective cohort 
study (N=222) found radiographically con-
fi rmed PE after fi lter placement in only 2% of 
patients with IVCFs after a mean follow-up of 
15 months.6 
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A retrospective cohort study (N=318) con-
cluded that 3.1% of the patients with IVCFs had 
a recurrent PE, diagnosed radiographically.7
A single-center retrospective cohort study 
of 1731 patients with IVCFs placed for various 
indications showed PE in 5.6% of patients. 
Some embolisms were clinically suspected 
and not confi rmed.8
Complications of ﬁ lter placement
Complications from IVCF placement gener-
ally occur less than 3% of the time. Th e most 
common complication is postthrombotic 
syndrome (70%). Risks associated with IVCF 
placement include DVT, postthrombotic syn-
drome, maldeployed fi lter, caval thrombosis, 
retroperitoneal hemorrhage, malposition, fi l-
ter migration, arrhythmia, insertion site com-
plications (such as infection or hematoma), 
PE, myocardial infarction, and death.1,2,5-12
Recommendations
Th e American College of Chest Physicians rec-
ommends considering an IVCF for patients 
with DVT who have a contraindication to an-
ticoagulation, complication of anticoagula-
tion, or recurrent thromboembolism despite 
adequate anticoagulation.12 
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